TALEN and SpCas9 RNP (SpCas9 protein + CD40LG sgRNA) were tested, in parallel, in mPB CD34+ HSPCs following the timeline outlined in Figure S1B. At matched rAAV6 multiplicity of infection (MOI), SpCas9 outperformed TALEN in preserving HSPC viability while enabling superior HDR efficiency (Figures S1C and S1D). The gene discussed is CD34; the disease is infection.